580 Views

Evaluation Video

AACE Annual Meeting

Satellite Symposia Dinner

An Update on Hypoparathyroidism and Hyperparathyroidism: Latest Treatment Guidelines and Consensus Recommendations

An Update on Hypoparathyroidism and Hyperparathyroidism: Latest Treatment Guidelines and Consensus Recommendations

Friday, May 13, 2022

7:00 PM – 9:00 PM

Location: Breakout Room 4-Aqua ABC (Level 3)

CME Credits: 1.5

Presenter(s)

Bart Clarke, MD
Professor of Medicine, Mayo Clinic College of Medicine
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic
Rochester, Minnesota, United States

Disclosure: Ascendis, Inc. (Self) : Research Grant (Status: Ongoing); Bristol Myers Squibb (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Data Monitoring Committee (Status: Ongoing); Chugai Pharmaceuticals (Self) : Research Grant (Status: Terminated --- 7/1/2021); Takeda (Self) : Research Grant (Status: Ongoing)
Aliya A. Khan, MD,FRCPC, FACP, FACE,FASBMR
Professor Of Clinical Medicine
McMaster University
Oakville, Ontario, Canada

Disclosure: Alexion (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing); Amgen (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing); Amolyt (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Ascendis (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Chugai (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing); Radius (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Takeda (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing); Ultragenyx (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing)

To claim credit, please visit https://www.excelcme.com/513

Planned by: Excel Continuing Education
Provided by an education grant from: Ascendis/Takeda

A multinational consortium of key opinion leaders, who are world specialists in hyperparathyroidism and hypoparathyroidism, convened virtually during the past couple of years to develop clinical practice guidelines and consensus recommendations to assist practitioner and patient decisions about appropriate healthcare for these two disorders. This information will be published in the Journal of Bone and Mineral Research in early 2022. The European Society of Endocrinology is also in the process of providing additional consensus statements. Our presenters, two panel members of the multinational consortium, will offer a review of the new guidelines including new changes, essential components, and consensus recommendations for clinical practice, namely assessment and monitoring, patient education, control of factors contributing to healthcare, and appropriate treatment, with a goal of improving the care of patients with these disorders.

Participants should be aware of the following financial/non-financial relationships:

Bart Clarke, MD: Ascendis, Inc. (Individual(s) Involved: Self): Research Grant; Bristol Myers Squibb (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Data Monitoring Committee; Chugai Pharmaceuticals (Individual(s) Involved: Self): Research Grant; Takeda (Individual(s) Involved: Self): Research Grant

Aliya A. Khan, MD,FRCPC, FACP, FACE,FASBMR : Alexion (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Honorarium, Research Grant; Amgen (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Honorarium, Research Grant; Amolyt (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Research Grant; Ascendis (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Research Grant; Chugai (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Honorarium, Research Grant; Radius (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Research Grant; Takeda (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Honorarium, Research Grant; Ultragenyx (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Honorarium, Research Grant